Acurox Approval Could Be Impossible Given Combination Drug Regs

By determining that the niacin component of King Pharmaceuticals/Acura Pharmaceuticals' Acurox, an abuse-resistant formulation of immediate-release oxycodone, is ineffective at deterring oral abuse of the opioid product, an FDA advisory committee may have precluded the possibility of approval, given the regulations governing combination products